|
Press Release: Cephalon reacquires rights to ACTIQ in key European markets; deal further strengthens international marketing presence.
Publication: Asia Africa Intelligence Wire Publication Date: 03-OCT-02 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2002 Financial Times Ltd.
(From Chemical Business NewsBase: Press Release)
Cephalon Inc has reacquired all rights to its cancer pain product ACTIQ (oral transmucosal fentanyl citrate) [C-II] in 12 countries, principally in Europe, from Elan Pharma International Ltd, a subsidiary of Elan Corp plc. Under the agreement, Cephalon reacquired rights to ACTIQ in...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Asia Africa Intelligence Wire |
A joyous and sweet time.
September 20, 2002
|
High-octane jazz in the port.
September 20, 2002
|
Living Legend.
September 20, 2002
|
Cats, bats and rats.
September 20, 2002
|
What's in a holiday?
September 20, 2002
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
